This sustained-release sulfonamide is commonly used to manage acute systemic and localized bacterial infections in susceptible cattle.

Uses and Symptom Support

It is relevant in contexts where additional symptomatic support is needed, primarily addressing symptoms related to systemic imbalance and respiratory distress in beef and non-lactating dairy cattle. The treatment is relevant for managing bacterial components in conditions such as Bovine Respiratory Disease Complex (BRDC), pneumonia, Foot Rot, and acute Metritis. In ruminating replacement calves, it helps address Colibacillosis (infectious scours) and Calf Diphtheria. It is considered relevant in contexts involving heightened systemic burden.

The sustained action of the bolus offers therapeutic continuity. The continuity of the therapeutic effect supports easing the overall symptom load during difficult episodes, assisting with maintaining functional stability for up to 72 hours. This prolonged benefit helps patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Systemic Burden
Commonly used to help manage symptoms associated with fever and acute systemic bacterial states.

Regulatory References

1. DailyMed NLM label for Sustain III Calf Bolus

Who can and cannot use Sustain III?

The population eligibility for the sustained-release antibiotic Sustain III (sulfamethazine) is strictly defined by government regulatory agencies, primarily to ensure the safety of food products through mandatory residue warnings.

Eligibility scope

Category	Regulatory Status
Populations Allowed	Beef cattle and non-lactating dairy cattle
Contraindicated Populations	Female dairy cattle 20 months of age or older (due to milk residue risk)
Age/Physiological Rules	Contraindicated in calves under one (1) month of age or those being fed an all-milk diet
Conditional Use	Use in all approved cattle requires a 12-day slaughter withdrawal period after the final dose

Official Eligibility Statements

• The drug is contraindicated in any animal with a known sensitivity to sulfonamides or a pre-existing renal impairment.
• It is not to be used in lactating dairy cattle.
• The product has not been shown to be effective for non-ruminating calves, and its use is restricted to ruminating replacement calves.

Connection to the overall eligibility profile

The eligibility profile strictly mandates that Sustain III be used only in beef cattle and non-lactating dairy cattle to comply with milk residue regulations. Absolute contraindications are placed on mature female dairy cattle and very young, non-ruminating calves to prevent violative drug residues in the food supply, with a mandatory 12-day withdrawal period for all treated animals prior to slaughter.

Interactions with Other Medicines and Products

Official regulatory documents and professional veterinary monographs define the interaction profile for Sulfadimidine (Sulfamethazine), the active ingredient in Sustain III, primarily based on pharmacodynamic and absorption-related effects. No mandatory timing-based separation rules are specified in the official labeling.

---

Documented Interaction Patterns

Interaction Type	Interacting Substances/Classes	Description of Official Finding
Synergistic Action	Diaminopyrimidines (e.g., Trimethoprim)	Results in a Potentiated Sulfonamide effect, formally recognized for enhanced anti-infective activity.
Reduced Absorption	Bile Acid Sequestrants (e.g., Cholestyramine, Colestipol)	Co-administration may reduce the gastrointestinal absorption of Sulfadimidine, leading to lower circulating concentrations.
Reduced Efficacy	PABA-Derivative Anesthetics (e.g., Chloroprocaine)	Co-administration may antagonize the sulfonamide's effect, reducing its intended activity.

---

Population-Specific Interaction Notes

Regulatory cautions advise that interactions or potential complications may be more pronounced in animals with impaired hepatic or renal function, necessitating careful management. Additionally, the product is restricted from use in calves under one month of age or those on an all-milk diet, due to altered drug clearance that could lead to unfavorable residue levels.

How Sustain III Works: Mechanism of Action

---

Targeted Inhibition of Bacterial Folate Synthesis

The core action of Sulfadimidine is centered on the competitive inhibition of the bacterial enzyme Dihydropteroate synthase (DHPS). This enzyme catalyzes the first committed step in the de novo synthesis of folic acid precursors, a pathway unique to susceptible microorganisms. By structurally mimicking the enzyme’s natural substrate, para-aminobenzoic acid (PABA), Sulfadimidine blocks this metabolic process at its earliest stage.

---

Achieving Bacteriostasis via Nucleic Acid Blockade

The blockade of folic acid synthesis rapidly leads to a deficiency in tetrahydrofolic acid (FH4) within the microbial cell. Since FH4 is indispensable for the synthesis of purine and pyrimidine bases—the fundamental building blocks of DNA and RNA—the bacteria are prevented from creating new genetic and structural material. This molecular cascade stops the susceptible pathogen from dividing and multiplying, a physiological consequence known as bacteriostasis, which limits the expansion of the bacterial population.

---

Mechanism Limitations: Competitive Constraints

The drug's mechanism is inherently subject to limitations arising from its competitive nature. The drug's inhibitory action is reduced in biological environments with high concentrations of PABA or its derivatives, such as in areas of extensive tissue necrosis or pus, as the natural substrate overcomes the competitive inhibition. Furthermore, bacterial resistance can emerge if the DHPS enzyme is genetically altered, lowering its binding affinity for Sulfadimidine and allowing the pathogen to bypass the inhibition.

Administration of Sustain III Boluses

Sustain III is a sulfonamide antibiotic designed for oral administration as a sustained-release bolus. The formulation is intended to provide a prolonged therapeutic level for approximately 72 hours (three days) from a single dose.

---

Dosing and Frequency

Dosing is based on the animal's body weight and the specific bolus strength used. The regimen is a single initial dose, with the potential for a repeat dose only after re-evaluation at the 72-hour interval. Exceeding two consecutive doses is cautioned against.

Bolus Strength	Target Population	Single Initial Dose
8.02 g (Calf)	Ruminating replacement calves	2 boluses per 100 lb body weight
32.1 g (Cattle)	Beef and non-lactating dairy cattle	1 bolus per 200 lb body weight

---

Administration Conditions and Population Rules

For proper administration, the bolus must be lubricated prior to dosing, and care must be taken to ensure the animal swallows the entire dose.

The bolus may be divided for a better dose approximation, but it must not be crushed to maintain its sustained-release function. Adequate fluid intake is required throughout the three-day therapy period.

The bolus is prohibited for use in calves under 1 month of age, calves on an all-milk diet, and female dairy cattle 20 months of age or older.

Research evidence / Overview of Studies for Sustain III

Evidence for the Control of Acute Systemic and Respiratory Infections

Research exploring the use of the sustained-release bolus for acute systemic conditions like Bovine Respiratory Disease Complex (BRDC) and bacterial pneumonia has involved both controlled clinical trials and supporting pharmacological studies. These studies were conducted primarily with beef cattle and non-lactating dairy cattle. Researchers monitored clinical efficacy endpoints, such as measurements related to changes in disease status, and outcomes related to physiological strain, like changes in fever or respiratory distress, which are used in research exploring how symptoms change over time.

Pharmacological research examined the design of the specialized bolus which was studied for its ability to release the active ingredient, Sulfadimidine, slowly. Research reported measurements suggesting that the specialized bolus formulation sustained concentrations of Sulfadimidine in the plasma for a defined period up to 72 hours. Trials that studied conditions such as Foot Rot and acute Metritis reported measurements related to changes in the status of these localized bacterial infections.

Studies Addressing Localized and Specific Bacterial Conditions

This sub-section describes the research framework that evaluated the medicine’s use in managing acute or disruptive episodes such as Foot Rot and Metritis. These investigations, often controlled clinical trials, monitored outcomes related to physical discomfort and systemic or functional imbalance associated with these conditions. Findings describe patterns observed in the studies related to changes in status of the specific bacterial causes, such as Fusobacterium necrophorum in Foot Rot.

Evidence for Use in Calf-Specific Bacterial Infections

Research exploring the use of the sustained-release bolus for conditions associated with acute or disruptive episodes, such as Colibacillosis and Calf Diphtheria, was evaluated in a defined patient group: ruminating replacement calves. These studies explored short-term symptom changes, focusing on outcomes related to functional imbalance and monitoring physiological strain in these younger animals.

Pharmacological findings indicate that a similar sustained-release pattern was examined in this population, showing patterns related to the concentrations of Sulfadimidine over the intended duration. Research highlights changes in status measured during the study period related to these infections.

Key Studies & References

1. NLM DailyMed Label: SUSTAIN III CALF- sulfamethazine sustained release calf tablet, extended release (NADA 120-615)

Common questions about Sustain III (FAQ)

---

Q: Are there any specific foods or drinks to avoid while using Sustain III?

A: Official labeling for use in calves states that this medication should not be used in calves that are currently being fed an all-milk diet. The official product information also stresses that adequate fluid intake must be maintained throughout the entire three-day course of therapy provided by the bolus.

Q: Are there special warnings about taking Sustain III in hot weather?

A: Regulatory information does not issue a specific warning for hot weather, but it does emphasize the general requirement for adequate fluid intake at all times during the three-day therapy period. This condition is described as essential for the proper use of the sustained-release medication.

Q: Is it okay to drive after taking Sustain III?

A: The official documents for this product contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves. Questions related to human activities like driving are irrelevant to its regulatory purpose.

Q: Is Sustain III the same as other similar-sounding medicines?

A: The active ingredient in Sustain III is Sulfamethazine, which belongs to the sulfonamide class of antibiotics. Medicines are identified and classified based on their specific active ingredient and unique formulation, which for Sustain III, is a sustained-release bolus.

Q: Can Sustain III be taken by people with kidney issues?

A: Official documents contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves, and is not evaluated for or intended for human use, including people with kidney issues.

Q: What are the most common reported side effects of Sustain III?

A: The regulatory cautions note that, like all sulfonamide-class drugs, this medicine 'may cause toxic reactions and irreparable injury' unless it is administered under adequate and continuous supervision by a veterinarian. For specific, non-serious effects, official materials should be consulted.

Q: Is Sustain III safe to take long-term, over many months or years?

A: The official documents outline a treatment regimen that starts with a single initial dose and allows for only one potential repeat dose after 72 hours if needed. Official limitations specifically caution against exceeding two consecutive doses, which defines the limited scope of use.

Q: Does Sustain III affect birth control pills?

A: Official documents contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves, making human-drug interaction information, such as with birth control pills, irrelevant.

Q: Is it normal to feel tired or dizzy when starting Sustain III?

A: Official documents contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves, and human side effect questions are not relevant to its regulatory purpose.

Q: What is the risk of a serious allergic reaction to Sustain III?

A: The regulatory caution states that this class of medicine 'may cause toxic reactions' and requires continuous supervision. This description represents the most serious stated risk in official materials. Specific common allergic reactions or anaphylaxis are not detailed in the general caution.

Q: Can people with a history of heart problems take Sustain III?

A: Official documents contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves, and is not evaluated for human use, including people with heart problems.

Q: Is Sustain III a controlled substance?

A: The official label describes Sustain III as a 'PRESCRIPTION ANIMAL DRUG.' Federal law restricts this drug to use only by or on the order of a licensed veterinarian, which requires professional oversight.

Q: Are there any limitations on physical activity while taking Sustain III?

A: Official documents contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves, making questions about human physical activity irrelevant.

Q: What is the main ingredient in Sustain III?

A: The active ingredient in Sustain III is Sulfamethazine, which belongs to the sulfonamide class of antibiotics.

Q: Is Sustain III safe for people who have diabetes?

A: Official documents contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves, and is not evaluated for human use, including people with diabetes.

Q: Does Sustain III cause dry mouth?

A: Official documents contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves, and human side effect questions are not relevant to its regulatory purpose.

Q: Is Sustain III available over-the-counter?

A: No. Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is classified as a prescription animal drug and is not available over-the-counter to the public.

Q: What does the FDA say about the safety profile of Sustain III?

A: The FDA approved this drug under NADA # 120-615. The label includes several Residue Warnings related to human consumption of treated meat and general cautions that the drug, like all sulfonamides, may cause toxic reactions unless administered with adequate supervision.

Q: Are there any common reasons why someone might need to switch from Sustain III to another drug?

A: Official guidelines state that if there is no positive response within 2 to 3 days of administration, the supervising veterinarian is advised to reevaluate the animal's therapy and consider alternative treatment options.

Q: Does Sustain III affect the ability to concentrate?

A: Official documents contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves, and human side effect questions are not relevant to its regulatory purpose.

Q: What is the shelf life or expiration guidance for Sustain III?

A: Official storage conditions recommend storing the product at room temperature, specifically 20 C to 25 C (68 F to 77 F). The specific expiration date for the drug is printed on the package.

Q: Are there specific official guidelines for discontinuing Sustain III use?

A: The official product information describes the treatment as a regimen with a re-evaluation interval of 72 hours. It also specifies a maximum number of doses and cautions against exceeding two consecutive doses.

Q: Can a patient take Sustain III if they have liver disease?

A: Official documents contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves, and is not evaluated for human use, including people with liver disease.

Q: Is the main use of Sustain III described as 'curative' or 'symptomatic relief'?

A: Official indications describe the drug for the treatment of specific bacterial diseases, such as Bacterial Pneumonia and Colibacillosis, caused by organisms sensitive to sulfamethazine.

Q: Are there known issues with taking Sustain III with alcohol?

A: Official documents contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves, making alcohol-related warnings for human consumption irrelevant.

Q: Does Sustain III interact with medications for depression or anxiety?

A: Official documents contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves, making human-drug interaction information, such as with psychiatric medications, irrelevant.

Q: Do any official sources define what constitutes a 'serious' side effect of Sustain III?

A: The regulatory caution states this drug, like all sulfonamides, 'may cause toxic reactions and irreparable injury' unless administered with adequate and continuous supervision. This general statement represents the most serious stated risk defined by official sources.

Q: Is Sustain III known to cause or worsen insomnia?

A: Official documents contain a prominent and important warning: 'NOT FOR HUMAN USE.' Sustain III is an approved prescription animal drug intended exclusively for use in cattle and calves, and human side effect questions are not relevant to its regulatory purpose.

How to Store and Dispose of Sustain III?

The storage and disposal of Sustain III Calf Boluses must strictly comply with the conditions defined in official regulatory labeling to ensure product stability and safety.

Storage Requirements

Sustain III must be stored at a Controlled Room Temperature, specifically defined as 20 C to 25 C (68 F to 77 F). The labeling permits brief temperature excursions between 15 C and 30 C. The product is designated as an animal drug and is NOT FOR HUMAN USE.

Child Safety and Disposal

It is a mandatory storage requirement that Sustain III be kept out of reach of children. Disposal of the contents and container must be carried out in accordance with local, regional, national, and international regulations to ensure environmentally responsible waste management.